• Profile
Close

Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer

BMC Cancer Jul 12, 2019

Hirahara T, et al. - In this retrospective analysis of patients (n=175) with advanced gastric cancer treated with chemotherapy, researchers assessed the neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) and the clinical usefulness of a new blood score joining the NLR and PLR (NLR-PLR score) to see if it could predict tumor response and prognosis. Based on tumor response, patients were defined as progressive disease (PD) or non-PD. Patients with a higher NLR-PLR score demonstrated a significantly poorer prognosis vs those with a lower NLR-PLR score. NLR-PLR score was identified as an independent prognostic factor for the prediction of overall survival in multivariate analysis, as it was significantly higher in patients with PD vs those with non-PD.

Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay